Last updated: February 6, 2026
What is the scope of the litigation?
The case involves Acorda Therapeutics accusing Teva Pharmaceuticals of patent infringement related to the drug Ampyra (dalfampridine). Acorda holds patent rights (U.S. Patent No. 8,798,278, among others) covering formulations and methods of using Ampyra. The core issue centers on whether Teva's generic version infringes those patents, and whether the patents are valid.
When was the litigation initiated and how has it progressed?
The lawsuit was filed on March 13, 2014, in the U.S. District Court for the District of Delaware. The proceedings encompass multiple motions, including patent infringement, validity challenges, and potential preliminary injunctions.
Key milestones:
- Initial filings: Accorda accused Teva of infringing on U.S. Patent No. 8,798,278, which covers a specific formulation of dalfampridine.
- Markman hearing: The court construed patent claim language in August 2015.
- Summary judgment motions: Filed in 2016, addressing validity and infringement issues.
- Patent trial: A jury verdict was issued in August 2017, with the court finding Teva infringed valid claims.
- Appeals and stay: Both parties appealed, with some proceedings stayed pending inter partes review (IPR) by the Patent Trial and Appeal Board (PTAB).
What are the critical patent issues?
- Validity of the patents: Teva challenged patent validity on grounds of obviousness, anticipation, and lack of patentable subject matter.
- Infringement: The dispute centers on whether Teva’s generic dapraline product infringes claims of the '278 patent, which claims a specific formulation with particular excipients and dosages.
How has the court addressed claim construction?
The court interpreted key claim terms, such as "consisting essentially of," to determine scope. Notably, the court clarified that:
- The term "consisting essentially of" limits claims to exclude other material ingredients unless they do not materially affect the basic and novel properties of the invention.
- Certain limitations related to particle size and dosage were construed narrowly or broadly, affecting infringement analyses.
What was the outcome of the infringement and validity findings?
In August 2017, a jury found:
- Infringement: Teva's generic infringed the asserted claims of the '278 patent.
- Validity: The patents were valid. The jury rejected Teva's obviousness and anticipation defenses.
Following the verdict:
- Acorda sought a preliminary injunction, which was denied in 2018.
- The court issued a permanent injunction in 2019 preventing Teva from launching its generic.
What post-trial and appeal proceedings occurred?
- Teva appealed the verdict, arguing claim construction and evidentiary issues.
- The Federal Circuit upheld the district court’s validity ruling but reversed on certain claim interpretation aspects, leading to remand in 2019.
- The dispute continues with ongoing IPR proceedings attempting to invalidate the patents, with PTAB rulings initially invalidating some patent claims, but those were appealed and stayed.
What is the current status?
As of 2023:
- The case remains active in district court with ongoing settlement negotiations.
- PTAB proceedings have had conflicting rulings; final determinations are pending final appeals.
- Teva is restricted from marketing its generic until final patent rulings clear.
Impact on the market and competition
This litigation delayed Teva’s generic Ampyra entry into the market, supporting Acorda’s market exclusivity. The conflict exemplifies how patent litigations over formulations influence drug pricing and generic competition timelines.
Key Takeaways
- Acorda held enforceable patent rights covering a specific formulation of dalfampridine.
- The court initially found for Acorda, providing a pathway for patent enforcement and market exclusivity.
- Teva challenged validity and claim scope, resulting in complex appeal and PTAB proceedings.
- Patent validity was upheld in the district court; subsequent PTAB decisions have fluctuated.
- The invalidation debates and ongoing appeals continue to affect the timing of generic Ampyra’s market entry.
FAQs
1. What is the significance of the '278 patent?
It covers a specific formulation of dalfampridine for multiple sclerosis, underpinning Acorda’s market exclusivity and blocking generic entry until patent expiry or invalidation.
2. Why did Teva challenge the patent’s validity?
Teva argued that the patent claims were obvious or anticipated based on prior art, aiming to nullify the patent and enable generic competition.
3. How does claim construction influence patent litigation?
It defines the scope of patent claims, determining infringement and validity. Differing interpretations can sway court outcomes significantly.
4. What role do PTAB proceedings play?
PTAB rulings can invalidate patent claims through inter partes reviews, impacting ongoing litigation and market exclusivity.
5. When can Teva launch a generic version of Ampyra?
Not until final patent rulings and a court-ordered stay expire. As of 2023, Teva remains restricted pending resolution of patent disputes.
References
[1] Court docket and rulings from U.S. District Court for the District of Delaware.
[2] Federal Circuit decisions and PTAB rulings.
[3] Acorda Therapeutics earnings and patent disclosures.
